In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents
Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)
DOI: 10.1128/aac.01363-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Mariana Castanheira und 5 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Anti-Bacterial Agents, Pseudomonas aeruginosa, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We subjected seven P . aeruginosa isolates to a 10-day serial passaging against five antipseudomonal agents to evaluate resistance levels post-exposure and putative resistance mechanisms in terminal mutants were analyzed by whole-genome sequencing analysis. Meropenem (mean, 38-fold increase), cefepime (14.4-fold), and piperacillin-tazobactam (52.9-fold) terminal mutants displayed high minimum inhibitory concentration (MIC) values compared to those obtained after exposure to ceftolozane-tazobactam (11.4-fold) and ceftazidime-avibactam (5.7-fold). Fewer isolates developed elevated MIC values for other β-lactams and agents belonging to other classes when exposed to meropenem in comparison to other agents. Alterations in nalC and nalD, involved in the upregulation of the efflux pump system MexAB-OprM, were common and observed more frequently in isolates exposed to ceftazidime-avibactam and meropenem. These alterations, along with ones in mexR and amrR, provided resistance to most β-lactams and levofloxacin but not imipenem. The second most common gene altered was mpl, which is involved in the recycling of the cell wall peptidoglycan. These alterations were mainly noted in isolates exposed to ceftolozane-tazobactam and piperacillin-tazobactam but also in one cefepime-exposed isolate. Alterations in other genes known to be involved in β-lactam resistance ( ftsI , oprD , phoP, pepA, and cplA ) and multiple genes involved in lipopolysaccharide biosynthesis were also present. The data generated here suggest that there is a difference in the mechanisms selected for high-level resistance between newer β-lactam/β-lactamase inhibitor combinations and older agents. Nevertheless, the isolates exposed to all agents displayed elevated MIC values for other β-lactams (except imipenem) and quinolones tested mainly due to alterations in the MexAB-OprM regulators that extrude these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- JMI Laboratories, North Liberty, Iowa, USA.
- The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
ORCID-Profile: Mariana Castanheira, John H Kimbrough, Helio S Sader
Zitieren
APA
Castanheira, M., Kimbrough, J. H., Lindley, J., Doyle, T. B., Ewald, J. M., & Sader, H. S. (2024). In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents. Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01363-23
Vancouver
Castanheira M, Kimbrough JH, Lindley J, Doyle TB, Ewald JM, Sader HS. In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents. Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01363-23
BibTeX
@article{Castanheira2024,
author = {Castanheira, Mariana and Kimbrough, John H and Lindley, Jill and Doyle, Timothy B and Ewald, Jessica M and Sader, Helio S},
title = {In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {5},
doi = {10.1128/aac.01363-23}
}
EUVIMED